Vaxart Inc (VXRT.OQ)
VXRT.OQ on NASDAQ Stock Exchange Capital Market
3.17USD
20 Jun 2018
3.17USD
20 Jun 2018
Change (% chg)
$0.04 (+1.28%)
$0.04 (+1.28%)
Prev Close
$3.13
$3.13
Open
$3.14
$3.14
Day's High
$3.17
$3.17
Day's Low
$3.14
$3.14
Volume
204
204
Avg. Vol
15,017
15,017
52-wk High
$11.88
$11.88
52-wk Low
$2.77
$2.77
About
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include... (more)
No analyst recommendations are available for .
Overall
| Beta: | 0.02 |
| Market Cap(Mil.): | $27.05 |
| Shares Outstanding(Mil.): | 38.65 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-Vaxart Appoints Dr. David Taylor As Chief Medical Officer
* VAXART APPOINTS DR. DAVID TAYLOR AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:
BRIEF-Vaxart Announces $5 Mln Inavir Revenue Milestone
* VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO
Competitors
| Price | Chg | |
|---|---|---|
| GlaxoSmithKline plc (GSK.L) | 1,558.40 | +8.40 |
| Gilead Sciences, Inc. (GILD.OQ) | $70.63 | -0.31 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 8,920.00 | +310.00 |
| Novavax, Inc. (NVAX.OQ) | $1.60 | -0.01 |
| Bavarian Nordic A/S (BAVA.CO) | kr.195.15 | -3.30 |
| Regeneron Pharmaceuticals Inc (REGN.OQ) | $331.98 | +4.91 |
| DAIICHI SANKYO COMPANY, LIMITED (4568.T) | ¥4,230 | +207.00 |
| CSL Limited (CSL.AX) | $193.81 | +2.16 |
| Shionogi & Co Ltd (4507.T) | ¥5,781 | +108.00 |
Earnings vs. 
Estimates